Back to search page

rdit20170526006

Research grant - Looking for pharmaceutical companies developing drugs and chemotherapeutics against leukemia and lymphoma.

RESEARCH PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

Researchers from an Italian university have tested a novel therapeutic approach to treat leukemia and lymphomas, consisting of polymeric nanoparticles (NPs) decorated with a targeting antibody and loaded with chemotherapeutic drugs. The group seeks to partner with pharmaceutical companies developing drugs and chemotherapeutics against leukemia and lymphoma. A regional grant will support the co-development of the research results by paying the costs of one year fellowship.


FULL DESCRIPTION

An Italian research group is proposing a novel therapeutic approach to treat leukemia and lymphomas, based on the use of polymeric nanoparticles (NPs) featuring a targeting monoclonal antibody (mAb) and a chemotherapeutic payload. The NPs are composed of biocompatible and biodegradable polymers and loaded with a combination of two drugs, chlorambucil and hydroxychloroquine, which showed a synergistic killing effect against neoplastic B-cells. Moreover, the antiCD20 mAb allows to target the NPs toward the CD20 antigen, which is expressed by most cancers related to B-cells neoplasia, including chronic lymphocytic leukemia (CLL) and several non-Hodgkin lymphomas.

Chemotherapy is the major form of therapy against leukemia and lymphoma and can be administered in different treatment protocols comprising combinations of multiple drugs. However, there is an urgent need for novel therapeutic strategies for difficult-to-treat cases, such as refractive patients. Another major challenge is to deliver the therapeutic agents to tumor cells while preserving the viability of non-malignant cells.

The research group has longstanding experience in international projects and collaborations.

They are looking for pharmaceuticals companies developing drugs and chemotherapeutics against leukemia and lymphoma (in particular drugs that target B-cells and CD20), and which are interested in promoting this solution into clinical phases. Pharmaceutical companies active in the veterinary field could be potentially highly interested to co-develop this technology and support the group in the in vivo therapeutic trials on dogs spontaneously affected by the disease. Other partners could be manufacturers of nanoparticles for drug delivery interested in investigating this targeting mechanism on their substrates.

Deadline of the call: 30/08/2017
Deadline for EoIs: 15/07/2017


Partner expertise sought:

- Specific area of activity of the partner: Potential partners for this technology are pharmaceuticals companies developing drugs and chemotherapeutics against leukemia and lymphoma (in particular drugs that target B-cells and CD20), and which are interested in promoting this solution into clinical phases. Pharmaceutical companies active in the veterinary field could be potentially highly interested to co-develop this technology and support the group in the in vivo therapeutic trials on dogs spontaneously affected by the disease. Other partners could be manufacturers of nanoparticles for drug delivery interested in investigating this targeting mechanism on their substrates.


Advantages & innovations:

The proposed drug delivery system is advantageous compared to the present chemotherapy treatments because, by loading two toxic agents within a biocompatible protecting scaffold, it consents the safe and targeted delivery of a high-dose of chemotherapeutics to tumor cells, reducing the necessary administered dose and the toxic side effects on healthy tissues. Furthermore, it exploits the biodistribution properties of targeted nanoparticles and their ability to cross cellular barriers and afford intracellular delivery of toxic insoluble drugs with a modified pharmacokinetic profile. Finally, the solution would allow to perform the therapeutic treatment avoiding invasive chirurgical and radio-therapeutic procedures.

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
ITALY
Profile date
26/06/2017
Deadline
26/06/2018

PARTNERSHIP(S) SOUGHT

Research cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Nanotechnology & Nanoscience \ Life Sciences \ Biosciences and Health \ Environment & Protecting Man \ Drug Discovery and Drug Development \ Diagnostics \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Clinical Research, Trials / BIOLOGICAL SCIENCES / Medicine, Human Health / Cytology, Cancerology, Oncology / BIOLOGICAL SCIENCES / Medicine, Human Health / Medical Research / BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs / BIOLOGICAL SCIENCES / Micro- and Nanotechnology related to Biological sciences
COMMERCIAL KEYWORDS
Research and experimental development on biotechnology
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Therapeutic / Therapeutic services / MEDICAL/HEALTH RELATED / Therapeutic / Drug delivery and other equipment / MEDICAL/HEALTH RELATED / Clinical Medicine / Oncology / MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals / MEDICAL/HEALTH RELATED / Plant and animal health / Animal health

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number rdit20170526006